ak104
Showing 1 - 25 of 25
AK104 Combined With I-125 Brachytherapy for Recurrent or
Not yet recruiting
- Cervical Cancer
- Iodine-125 particle brachytherapy
- AK104
- (no location specified)
Sep 25, 2023
Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, AK104, caboplatin)
Not yet recruiting
- Advanced Non-small-cell Lung Cancer
- AK112
- +5 more
-
Shanghai, ChinaShanghai Pulmonary Hospital
Jun 6, 2023
Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)
Not yet recruiting
- Locally Advanced Rectal Cancer
- AK104
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 5, 2023
Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)
Recruiting
- Muscle Invasive Bladder Carcinoma
- RC48-ADC
- AK104
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023
Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)
Recruiting
- Gastric Cancer
- AK104
- +3 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 7, 2023
Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma Trial in Chengdu (AK104, Axitinib)
Not yet recruiting
- Renal Cell Carcinoma
- +3 more
- AK104
- Axitinib
-
Chengdu, Sichuan, ChinaWest China Hospital
Apr 10, 2023
Vulvar Cancer Trial in China (AK104)
Not yet recruiting
- Vulvar Cancer
- AK104
-
Fuzhou, Fujian, China
- +5 more
Jun 27, 2023
Solid Tumor, Adult Trial in Tianjin (AK119, AK104)
Recruiting
- Solid Tumor, Adult
- AK119
- AK104
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insitute & Hospital
Dec 28, 2022
Pancreatic Cancer Trial in China (AK104, Gemcitabine, Nab-Paclitaxel)
Not yet recruiting
- Pancreatic Cancer
- AK104
- +2 more
-
Beijing, Beijing, China
- +6 more
May 5, 2023
Esophageal Squamous Cell Carcinoma Trial (AK104)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- AK104
- (no location specified)
Oct 25, 2022
Carcinomas, Cervix Cancer, Cervical Cancer Trial in Houston (AK104)
Recruiting
- Carcinomas
- +2 more
- AK104
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- AK104
- Lenvatinib
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Oct 17, 2022
MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)
Terminated
- MSI-H/dMMR Solid Tumor
- AK104
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Oct 17, 2022
Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)
Recruiting
- Advanced Malignant Tumors
- AK104
- +8 more
-
Shanghai, ChinaShanghai Renji Hospital
Aug 9, 2022
Unresectable, Non-metastatic Hepatocellular Carcinoma Trial in China (biological, drug, procedure)
Recruiting
- Unresectable, Non-metastatic Hepatocellular Carcinoma
- AK104
- +2 more
-
Beijing, Beijing, China
- +4 more
Aug 11, 2022
NSCLC Trial in Zhengzhou (AK104)
Not yet recruiting
- Non-small Cell Lung Cancer
- AK104
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
May 16, 2022
Cervical Cancer Trial in Hanzhong (AK104)
Not yet recruiting
- Cervical Cancer
- AK104
-
Hanzhong, Zhejiang, ChinaZhejiang Cancer Hospital
Jan 27, 2022
Locally Advanced Cervical Carcinoma Trial in China (AK104, EBRT, BT)
Recruiting
- Locally Advanced Cervical Carcinoma
- AK104
- +4 more
-
Beijing, Beijing, China
- +9 more
Aug 22, 2022
Advanced NSCLC Trial in Nanjing (AK104, Docetaxel)
Recruiting
- Advanced Non-small Cell Lung Cancer
- AK104
- Docetaxel
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Mar 24, 2022
Clear Cell Renal Cell Carcinoma, First-line Treatment Trial in Shanghai (AK104, axitinib)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- First-line Treatment
- AK104
- axitinib
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 16, 2022
Recurrent or Metastatic Cervical Cancer Trial in Changsha, Hangzhou (AK104, Bevacizumab, Paclitaxel)
Active, not recruiting
- Recurrent or Metastatic Cervical Cancer
- AK104
- +3 more
-
Changsha, Hunan, China
- +1 more
Mar 28, 2022
Cervical Cancer Trial in Hangzhou, Hefei, Shanghai (AK104, paclitaxel, carboplatin)
Recruiting
- Cervical Cancer
- AK104
- +5 more
-
Hangzhou, China
- +4 more
Apr 26, 2022
Locally Advanced or Metastatic NSCLC Trial in China (AK104, Tislelizumab, carboplatin)
Not yet recruiting
- Locally Advanced or Metastatic NSCLC
- AK104
- +4 more
-
Bengbu, Anhui, China
- +61 more
Aug 10, 2023
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer Trial (AK104)
Not yet recruiting
- MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
- AK104
- (no location specified)
Sep 14, 2020
Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (AK104, Oxaliplatin,
Unknown status
- Gastric Adenocarcinoma
- +2 more
- AK104
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Feb 22, 2019